%0 Journal Article
%T Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)?
%A Bill Elliot Cham
%J Journal of Cancer Therapy
%P 33-47
%@ 2151-1942
%D 2024
%I Scientific Research Publishing
%R 10.4236/jct.2024.152004
%X Non-melanoma skin cancers or keratinocyte cancers such as basal cell
carcinoma and squamous cell carcinoma make up approximately 80% and 20%
respectively, of skin cancers with the 6 million people that are treated
annually in the United States. 1 in 5 Americans and 2 in 3 Australians develop
skin cancer by the age of 70 years and in Australia it is the most expensive,
amassing $1.5 billion, to treat cancers. Non-melanoma skin cancers are often
self-detected and are usually removed by various means in doctors<span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">กฏ</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> surgeries. Mohs micrographic surgery is acclaimed
to be the gold standard for the treatment of skin cancer. However, a novel
microscopic molecular-cellular non-invasive topical therapy described in this
article, challenges the status of Mohs procedure for being the acclaimed gold
standard.</span></span></span>
%K Skin Cancer
%K Basal Cell Carcinoma
%K Squamous Cell Carcinoma
%K Mohs Surgery
%K Microscopic Molecular-Cellular
%K Curaderm
%K Actinic Keratosis
%K Cosmesis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=131482